Page results
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
A new surgical technique could remove the risk of urinary incontinence after surgery to remove the prostate for men with prostate cancer.
-
A UCLH rheumatology team is leading an exciting project to help understand the reasons for young people missing their hospital appointments and find ways to improve this.
-
Information on how we ask for your consent to treatment, and Martha's Rule.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
This page is for patients receiving steroids for immunotherapy toxicity.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
Update about our hospital on Gray's Inn Road
File results
-
FOI/2024/0702 - Community respiratory service mapping/ community-based bronchiectasis services
-
FOI/2024/0703 - Neurofibromatosis type 1 treatment/ volume of medication dispensed
-
FOI/2024/0704 - Contingencies to support visitors/ patients/ contractors witnessing a distressing event
-
FOI/2024/0709 - Number of dilation and curettage operations for miscarriages 2019-2024
-
FOI/2024/0712 - Occupational health services, spend/ in-house/ outsourced 2021/22-2023/24
-
FOI/2024/0716 - Toxicological screening/ testing/ training and information to patients
-
FOI/2024/0718 - Mental health/ electronic health records software/ dermatology screening/ imaging services/ medical devices for wound care
-
FOI/2024/0719 - Tenders and prices for interpretation services
-
FOI/2024/0720 - Motion picture licensing corporation
-
FOI/2024/0721 - New biologic and targeted medications/ treatment within dermatology